Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 210

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial

Open access
Lheureux, Stephanie, Cristea, Mihaela C, Bruce, Jeffrey P, Garg, Swati, Cabanero, Michael, Mantia-Smaldone, Gina, Olawaiye, Alexander B, Ellard, Susan L, Weberpals, Johanne I, Wahner Hendrickson, Andrea E, Fleming, Gini F, Welch, Stephen, Dhani, Neesha C, Stockley, Tracy, Rath, Prisni, Karakasis, Katherine, Jones, Gemma N, Jenkins, Suzanne, Rodriguez-Canales, Jaime, Tracy, Michael, Tan, Qian, Bowering, Valerie, Udagani, Smitha, Wang, Lisa, Kunos, Charles A, Chen, Eric, Pugh, Trevor J, Oza, Amit M·2021·The Lancet

Abstract

Summary Background The Wee1 inhibitor adavosertib (AZD1775/MK1775) and gemcitabine demonstrated preclinical synergy and promising activity in early-phase clinical trials. Methods Women with measurable recurrent platinum-resistant/-refractory high-grade serous ovarian cancer were randomised 2:1 to receive intravenous gemcitabine (1000 mg/m2 on days 1, 8, and 15) with either oral adavosertib (175 mg) or placebo (once daily on days 1, 2, 8, 9, 15, and 16) every 28 days until progression or unacceptable toxicity. The primary endpoint was progression-free survival. Potential predictive factors were analysed using archival tissue (TP53 mutations by Sanger sequencing and immunohistochemistry) and paired tumour biopsies (by whole-exome and RNA sequencing). The trial is registered with ClinicalTrials.gov, NCT02151292. Findings Overall, 99 patients were randomised (65 to adavosertib–gemcitabine, 34 to placebo–gemcitabine). Progression-free survival was longer with adavosertib–gemcitabine (hazard ratio, 0·55; 95% confidence interval, 0·35–0·90; log-rank p=0·015; median 4·6 months with adavosertib–gemcitabine vs 3·0 months with placebo–gemcitabine). The most frequent grade ≥3 adverse events were haematological (neutropenia in 38/61 [62%] of adavosertib–gemcitabine-treated patients vs 10/33 [30%] of placebo–gemcitabine-treated patients; thrombocytopenia in 19/61 [31%] vs 2/33 [6%]). Homologous recombination deficiency, BRCA1/2 mutations, and CCNE1 amplification were associated with enhanced benefit from adavosertib but SLFN11 levels did not predict benefit from adavosertib–gemcitabine. Interpretation Adding adavosertib to gemcitabine significantly improved progression-free survival and overall survival in platinum-resistant/-refractory ovarian cancer. Combining gemcitabine with adavosertib increased toxicities, particularly haematological events. Patients with homologous repair gene mutations may benefit from adavosertib. Funding United States National Cancer Institute, US Department of Defense, Princess Margaret Cancer Foundation and AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)32554-x

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 210

Metadata

Authors
Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., Fleming, G. F., Welch, S., Dhani, N. C., Stockley, T., Rath, P., Karakasis, K., Jones, G. N., Jenkins, S., Rodriguez-Canales, J., Tracy, M., Tan, Q., Bowering, V., Udagani, S., Wang, L., Kunos, C. A., Chen, E., Pugh, T. J., & Oza, A. M.
Venue
The Lancet
Publisher
Elsevier BV
Published
2021-01
Volume
397
Issue
10271
Pages
281-292
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3122624214
Cited by
210
References
8
FWCI
27.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)32554-x
The paper
Lheureux, S., Cristea, M. C., Bruce, J. P., Garg, S., Cabanero, M., Mantia-Smaldone, G., Olawaiye, A. B., Ellard, S. L., Weberpals, J. I., Wahner Hendrickson, A. E., Fleming, G. F., Welch, S., Dhani, N. C., Stockley, T., Rath, P., Karakasis, K., Jones, G. N., Jenkins, S., Rodriguez-Canales, J., . . . Oza, A. M. (2021). Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)32554-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.